Literature DB >> 6708494

Effects of ibuprofen on a porcine model of acute respiratory failure.

R Kopolovic, K M Thrailkill, D T Martin, T Ambrose, M Vento, L C Carey, C T Cloutier.   

Abstract

Blockade of the arachidonic acid cascade has been shown to improve survival and hemodynamic alterations in animal models of sepsis and acute respiratory failure (ARF). The effects of intravenous ibuprofen, a cyclooxygenase inhibitor, were observed in 20-30 kg pigs with ARF induced by a continuous LD100 infusion of live Pseudomonas aeruginosa (2 X 10(8)/20 kg/min). Cardiopulmonary parameters were monitored in animals intubated, paralyzed, and ventilated at a 250-ml tidal volume and 0.5 FiO2. Pigs were randomly assigned to three groups: Group I received 2 bolus infusions of ibuprofen (12.5 mg/kg) at 20 and 210 min after baseline; Group II had Ps. aeruginosa (2 X 10(8) CFU/20 kg/min) only; Group III received Ps. aeruginosa and 12.5 mg/kg of ibuprofen at 20 and 210 min of ARF. Ibuprofen alone caused no significant changes in cardiorespiratory parameters. With Ps. aeruginosa infusion, significant pulmonary hypertension, hypoxemia, increased intrapulmonary shunt fraction, and systemic hypotension occurred. In the septic animals treated with ibuprofen, oxygenation was improved by a significant decrease in shunt, pulmonary edema, and pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6708494     DOI: 10.1016/0022-4804(84)90103-3

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

1.  Effects of ibuprofen on the physiology and outcome of rabbit endotoxic shock.

Authors:  Ilhami Celik; Ayhan Akbulut; S Sirri Kilic; Ali Rahman; Pervin Vural; Mukaddes Canbaz; Suleyman Felek
Journal:  BMC Infect Dis       Date:  2002-10-31       Impact factor: 3.090

Review 2.  Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes.

Authors:  Aman Rajpal; Leili Rahimi; Faramarz Ismail-Beigi
Journal:  J Diabetes       Date:  2020-09-02       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.